DeepToday
FDA delays LEQEMBI weekly Alzheimer's drug by three months
FDA extended review of Eisai's weekly subcutaneous lecanemab formulation to August 24, 2026, signaling continued scrutiny of anti-amyloid Alzheimer's therapies despite recent approvals.